JiangSu WuZhong Pharmaceutical Development News

Jiangsu Wuzhong (600200) 2024 three-quarter report review: Aisufei can be expected to continue to grow in high-growth medical and aesthetic business

soochow securitiesOct 22, 2024 07:46

Jiangsu Wuzhong (600200): Aisufei continues strong sales in the off-season and maintains annual growth targets

Fangzheng SecuritiesOct 21, 2024 00:00

Jiangsu Wuzhong (600200): Successful promotion of Aisufei in 24Q2

Aug 31, 2024 10:56

Jiangsu Wuzhong (600200): 24H1 deduction for non-high-growth medical and aesthetic business progresses smoothly

Aug 29, 2024 19:51

Deep* Company* Jiangsu Wuzhong (600200): Profit side improved significantly in the second quarter, and the medical and aesthetic business performed well

Aug 29, 2024 16:21

Jiangsu Wuzhong (600200): Aisufei's sales exceed expectations and are expected to achieve sales targets with high quality

Aug 29, 2024 00:00

Jiangsu Wuzhong (600200): Aisufei's rapid release of Tongyan acupuncture is optimistic about the space for medical and aesthetic business growth

Aug 28, 2024 14:02

Jiangsu Wuzhong (600200): Laying out PDRN regenerated water light to continue to enrich medical and aesthetic pipelines

Aug 1, 2024 00:00

Jiangsu Wuzhong (600200): Investment layout of PDRN products and diversified medical and aesthetic pipelines are being improved

Jul 30, 2024 19:02

Jiangsu Wuzhong (600200): Invest in the layout of regenerated water light PDRN medical and aesthetic pipelines

Jul 30, 2024 08:56

Jiangsu Wu Zhong (600200): Taking the lead in laying out recycled water light PDRN “baby needle” medical and aesthetic product matrix to further improve

Jul 29, 2024 00:00

Jiangsu Wuzhong (600200): Losses have narrowed in 23 years and recently, Tongyan acupuncture has been on the market

May 6, 2024 18:46

Jiangsu Wu Zhong (600200): Revenue increased 15% in 24Q1 and expected to release AESTHEFILL baby acupuncture

Apr 28, 2024 11:36

Shanghai Securities released a research report on April 28 stating that it gave Jiangsu Wu Zhong (600200.SH) a buy rating. The main reasons for the rating include: 1) the company's medical and aesthetic product Aesofei has been officially approved and is

Zhitong FinanceApr 28, 2024 09:52

BOC Securities released a research report on April 26 stating that it gave Jiangsu Wu Zhong (600200.SH) a buy rating. The main reasons for the rating include: 1) the company's revenue side performance is growing steadily, and the gross margin of the pharm

Zhitong FinanceApr 26, 2024 21:45

Minsheng Securities released a research report on April 26 stating that it gave Jiangsu Wu Zhong (600200.SH) a careful recommendation rating. The main reasons for the rating include: 1) the pharmaceutical business contributes the main revenue, and the gro

Zhitong FinanceApr 26, 2024 12:24

Jiangsu Wuzhong (600200): Pharmaceutical business is steady, and Aisufei's accelerated growth is expected

Apr 26, 2024 00:00

Deep* Company* Jiangsu Wuzhong (600200): Revenue side growth is steady, medical and aesthetic products approved for listing can be expected in the future

Apr 26, 2024 00:00

Jiangsu Wu Zhong (600200): 1Q24 revenue increased 15%, and the marketing volume of baby acupuncture can be expected

Apr 25, 2024 13:41

Jiangsu Wuzhong (600200) First In-depth Report: The steady development of the pharmaceutical business and the medical and aesthetic business have become a new highlight

Feb 19, 2024 15:41